Navigation Links
New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy
Date:4/29/2010

his,'o','ExternalLink');" target='_blank' href="http://www.springer.com/medicine/oncology/journal/10549">http://www.springer.com/medicine/oncology/journal/10549.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CAP-accredited and CLIA compliant service laboratories. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, Calif
'/>"/>

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study
2. Facet Solutions Announces 2 Year Data from US Pilot Study
3. Another Top 10 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac
4. Magnetic fields drive drug-loaded nanoparticles to reduce blood vessel blockages in an animal study
5. Study shows potential benefit of dark chocolate for liver disease patients
6. Study shows that size affects structure of hollow nanoparticles
7. ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
8. Australia Substantially Increases Research Collaboration with China, According to Thomson Reuters Study
9. New Study Shows Nu-Tek's Modified Potassium Chloride Improves Yields in Meat Processing
10. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
11. Study quantifies the electron transport effects of placing metal contacts onto graphene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... ... States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation ... ... for marketing by the United States Food and Drug Administration (K083292) of its Habib™ ...
... , , ARLINGTON, Va., July ... today from GPhA President and CEO Kathleen Jaeger on the Senate ... "While we are extremely disappointed that the Committee action ... biogenerics, we will continue to fight in the House to ensure ...
... National Institutes of Health have turned simple baker,s yeast into ... for drugs to treat Parkinson,s disease. In a study ... researchers showed that they can rescue yeast cells from toxic ... the cells to make very small proteins called cyclic peptides. ...
Cached Biology Technology:EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours 2GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients 2Novel drug discovery tool could identify promising new therapies for Parkinson's disease 2Novel drug discovery tool could identify promising new therapies for Parkinson's disease 3Novel drug discovery tool could identify promising new therapies for Parkinson's disease 4
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... of Medicine researchers have discovered how the membrane protein ... this protein becomes desensitized so that one no longer ... an advance online publication by Nature Neuroscience, focused on ... found in many other receptors, including ones involved in ...
... self-replicating, mineralizing agent, has been identified by National Aeronautics ... in kidney stone formation among astronauts. With the potential ... Mars, longer missions, and exposure to the elements of ... , To further comprehend the implications of NB, trials ...
... sclerosis (MS) can be an unpredictable disease. It ... nerve cells and disrupts normal nerve signaling. Patients ... pain, fatigue, and blurred vision—that can appear independently ... appear in no particular order, flare-ups are common ...
Cached Biology News:Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients 2
... transporter 2 (APT2) (Peptide ... PSF2) (Peptide supply factor ... involved in antigen processing ... Antigen: Recombinant ...
... epitope specific for Nabeta2 is ... known proteins.,SPECIES REACTIVITIES: It ... human because the immunogen sequence ... Reactivity with other species has ...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Biology Products: